Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $380 from $370 and keeps a Hold rating on the shares. The company posted a “solid” Q3 organic revenue beat and boasts one of the better growth profiles in large cap MedTech, with several new launch areas set to build momentum into Q4 and FY25, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: